New hope for Hard-to-Treat cancers: experimental drug MK-6837 enters human testing
NCT ID NCT06460961
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This early-stage study tests an experimental drug called MK-6837, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 168 adults with various advanced cancers are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health System Morristown Medical Center ( Site 4001)
Morristown, New Jersey, 07960, United States
-
Princess Margaret Cancer Centre ( Site 2001)
Toronto, Ontario, M5G 2M9, Canada
-
Providence Portland Medical Center ( Site 4002)
Portland, Oregon, 97213, United States
-
Sheba Medical Center-ONCOLOGY ( Site 3001)
Ramat Gan, 5265601, Israel
-
South Texas Accelerated Research Therapeutics (START) ( Site 4003)
San Antonio, Texas, 78229, United States
-
The Alfred Hospital ( Site 1001)
Melbourne, Victoria, 3004, Australia
-
Westmead Hospital ( Site 1002)
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.